Zai Lab

Biotech & Life Sciences · Pudong, China · Founded 2014 · IPO 2017

Built on a vision that China would be the next destination for the pharmaceutical and healthcare industry MoreLess

Zai Lab is a biopharmaceutical company focused on developing and commercializing innovative therapies for oncology, infectious diseases, and autoimmune disorders. The company serves patients with unmet medical needs, primarily in China and the Asia-Pacific region. Operating in the highly competitive biopharmaceutical market, Zai Lab collaborates with global partners to license and develop cutting-edge treatments. The business model revolves around research and development (R&D), clinical trials, and commercialization of novel drugs. Revenue is generated through product sales, licensing agreements, and strategic partnerships. Zai Lab's facilities in Suzhou, China, are designed to meet international standards, ensuring high-quality manufacturing of small molecule and biologic drugs.

Keywords: biopharmaceutical, oncology, infectious diseases, autoimmune disorders, R&D, clinical trials, commercialization, China, Asia-Pacific, innovative therapies.

Valuation $1.63B

Revenue $448M

Total funding $500M–1B

Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Talent graph

Zai Lab's talent

Book a demo to see the people

Team profiled 13 named & role-tagged

Founders /100 quality score

Key operators 3 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

11 investors on Zai Lab's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 6 investors entered at this stage

Qiming Venture Partners

Kleiner Perkins

Sequoia

TF Capital

Advantech Capital

OrbiMed

Series B+ 5 investors entered at this stage

Vivo Capital

Rock Springs Capital

Cormorant Asset Management

Bank of Communications

Industrial Bank

Global footprint

Where Zai Lab has talent and traffic

Workforce by country

7 countries with
team presence

🇨🇳 China75.3%

🇺🇸 United States18.7%

🇭🇰 Hong Kong3.9%

🇹🇼 Taiwan0.9%

🇸🇬 Singapore0.6%

Top 5 of 7 shown

Web traffic by country

20K monthly visits
across markets

🇺🇸 United States38%

🇨🇦 Canada19%

🇮🇳 India8%

🇬🇧 United Kingdom7.5%

🇭🇰 Hong Kong7%

Top 5 markets shown

Patent intelligence

$10M patent portfolio · 9 active families

Estimated portfolio value

$10M

0.61% of market cap · 9.1× smaller than top peer Alector ($91M)

9 active patent families

Where Zai Lab innovates Anti antibodyAntiendomysial antibodiesCancer researchCarcinosisDisease

Where Zai Lab concentrates vs peers

Each axis is a top-10 topic across Zai Lab and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Zai Lab

An AI-synthesized read of the highest-engagement posts about Zai Lab on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Zai Lab on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles